Results 261 to 270 of about 72,161 (311)
Some of the next articles are maybe not open access.
GIP’s effect on bone metabolism is reduced by the selective GIP receptor antagonist GIP(3–30)NH2
Bone, 2020Infusion of the incretin hormone glucose-dependent insulinotropic polypeptide (GIP) suppresses the bone resorption marker carboxy-terminal type 1 collagen crosslinks (CTX). Using separate and combined infusions of the selective GIP receptor (GIPR) antagonist, GIP(3-30)NH2, and GIP, we investigated how GIPR inhibition affects bone turnover markers.
Lærke S. Gasbjerg +8 more
openaire +5 more sources
Diabetes, obesity and metabolism, 2021
The incretin hormones glucose‐dependent insulinotropic polypeptide (GIP) and glucagon‐like peptide‐1 (GLP‐1) have their main physiological role in augmenting insulin secretion after their nutrient‐induced secretion from the gut.
M. Nauck +3 more
semanticscholar +1 more source
The incretin hormones glucose‐dependent insulinotropic polypeptide (GIP) and glucagon‐like peptide‐1 (GLP‐1) have their main physiological role in augmenting insulin secretion after their nutrient‐induced secretion from the gut.
M. Nauck +3 more
semanticscholar +1 more source
Proceedings of the first workshop on Wireless mobile internet, 2001
The GPRS and UMTS specifications define the procedures supporting the mobility and the data sessions of a mobile user moving within the area of the corresponding PLMNs. For the case, though, of mobile users working in group, using a PLMN infrastructure, the aforementioned networks foresee no special treatment.
Constantinos F. Grecas +2 more
openaire +1 more source
The GPRS and UMTS specifications define the procedures supporting the mobility and the data sessions of a mobile user moving within the area of the corresponding PLMNs. For the case, though, of mobile users working in group, using a PLMN infrastructure, the aforementioned networks foresee no special treatment.
Constantinos F. Grecas +2 more
openaire +1 more source
Journal of Clinical Endocrinology and Metabolism, 2022
AIMS/HYPOTHESIS Glucose-dependent insulinotropic polypeptide (GIP) has been proposed to exert insulin-independent effects on lipid and bone metabolism. We investigated the effect of a 6-day s.c.
Sebastian M N Heimbürger +18 more
semanticscholar +1 more source
AIMS/HYPOTHESIS Glucose-dependent insulinotropic polypeptide (GIP) has been proposed to exert insulin-independent effects on lipid and bone metabolism. We investigated the effect of a 6-day s.c.
Sebastian M N Heimbürger +18 more
semanticscholar +1 more source
Annals of Surgery, 2020
OBJECTIVE To perform a structured systematic review and meta-analysis to evaluate changes in ghrelin, glucagon-like peptide-1 (GLP-1), peptide YY (PYY), and gastric inhibitory peptide (GIP) gut hormone levels in patients after sleeve gastrectomy ...
T. McCarty, P. Jirapinyo, C. Thompson
semanticscholar +1 more source
OBJECTIVE To perform a structured systematic review and meta-analysis to evaluate changes in ghrelin, glucagon-like peptide-1 (GLP-1), peptide YY (PYY), and gastric inhibitory peptide (GIP) gut hormone levels in patients after sleeve gastrectomy ...
T. McCarty, P. Jirapinyo, C. Thompson
semanticscholar +1 more source
Peptides, 1981
Two structurally similar peptides were isolated from a preparation of GIP using an HPLC system. The major peptide corresponds to GIP1-42 and the minor has the sequence GIP3-42. GIP1-42 has both insulinotropic and somatostatinotropic activities, whereas GIP3-42 has only insignificant activity.
J C, Brown +5 more
openaire +2 more sources
Two structurally similar peptides were isolated from a preparation of GIP using an HPLC system. The major peptide corresponds to GIP1-42 and the minor has the sequence GIP3-42. GIP1-42 has both insulinotropic and somatostatinotropic activities, whereas GIP3-42 has only insignificant activity.
J C, Brown +5 more
openaire +2 more sources
Journal of Parkinson's Disease, 2020
Background: Parkinson’s disease (PD) is a progressive neurodegenerative disease for which there is no cure. In a clinical trial, the glucagon-like peptide-1 (GLP-1) receptor agonist exendin-4 has shown good protective effects in PD patients.
Lingyu Zhang +6 more
semanticscholar +1 more source
Background: Parkinson’s disease (PD) is a progressive neurodegenerative disease for which there is no cure. In a clinical trial, the glucagon-like peptide-1 (GLP-1) receptor agonist exendin-4 has shown good protective effects in PD patients.
Lingyu Zhang +6 more
semanticscholar +1 more source